British Journal of Clinical Pharmacology

Editors' report, November 2011
pp. 159-160(2)
Authors: Somogyi, Andrew A.; Lewis, Lionel D.; Cohen, Adam F.; Ferro, Albert; Loke, Yoon K.; Ritter, James M.

What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists
pp. 161-169(9)
Author: Aronson, Jeffrey K.

Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited
pp. 170-174(5)
Authors: Teschke, Rolf; Sarris, Jerome; Schweitzer, Isaac

Positron emission tomography molecular imaging for drug development
pp. 175-186(12)
Authors: Matthews, Paul M.; Rabiner, Eugenii A.; Passchier, Jan; Gunn, Roger N.

Pre-hypertension: how low to go and do drugs have a role?
pp. 187-193(7)
Author: McInnes, Gordon

Junior doctors prescribing: enhancing their learning in practice
pp. 194-202(9)
Authors: Rothwell, Charlotte; Burford, Bryan; Morrison, Jill; Morrow, Gill; Allen, Maggie; Davies, Carol; Baldauf, Beate; Spencer, John; Johnson, Neil; Peile, Ed; Illing, Jan

Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study
pp. 203-209(7)
Authors: Mendzelevski, Boaz; Ausma, Jannie; Chanter, Dennis O.; Robinson, Patricia; Kerstens, Rene; Vandeplassche, Lieve; Camm, John

Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein
pp. 210-218(9)
Authors: Boettcher, Michael-Friedrich; Heinig, Roland; Schmeck, Carsten; Kohlsdorfer, Christian; Ludwig, Matthias; Schaefer, Anja; Gelfert-Peukert, Sabine; Wensing, Georg; Weber, Olaf

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling
pp. 219-231(13)
Authors: Weber, Olaf; Willmann, Stefan; Bischoff, Hilmar; Li, Volkhart; Vakalopoulos, Alexandros; Lustig, Klemens; Hafner, Frank-Thorsten; Heinig, Roland; Schmeck, Carsten; Buehner, Klaus

Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420
pp. 232-239(8)
Authors: Tan, Tricia M.; Field, Benjamin C. T.; Minnion, James S.; Cuenco-Shillito, Joyceline; Chambers, Edward S.; Zac-Varghese, Sagen; Brindley, Charlie J.; Mt-Isa, Shahrul; Fiorentino, Francesca; Ashby, Deborah; Ward, Ian; Ghatei, Mohammad A.; Bloom, Stephen R.

Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
pp. 240-247(8)
Authors: Joerger, Markus; Ferreri, Andrés J. M.; Krähenbühl, Stephan; Schellens, Jan H. M.; Cerny, Thomas; Zucca, Emanuele; Huitema, Alwin D. R.

Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies
pp. 248-256(9)
Authors: Shintaku, Kyohei; Hori, Satoko; Satoh, Hiroki; Tsukimori, Kiyomi; Nakano, Hitoo; Fujii, Tomoyuki; Taketani, Yuji; Ohtani, Hisakazu; Sawada, Yasufumi

CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast
pp. 257-267(11)
Authors: Karonen, Tiina; Neuvonen, Pertti J.; Backman, Janne T.

Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes
pp. 268-284(17)
Authors: Yang, Junling; He, Minxia M.; Niu, Wei; Wrighton, Steven A.; Li, Li; Liu, Yang; Li, Chuan

Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity
pp. 285-294(10)
Authors: Craig, Darren G. N.; Bates, Caroline M.; Davidson, Janice S.; Martin, Kirsty G.; Hayes, Peter C.; Simpson, Kenneth J.

Clomipramine concentration and withdrawal symptoms in 10 neonates
pp. 295-302(8)
Authors: ter Horst, Peter G. J.; van der Linde, Susanne; Smit, Jan Pieter; den Boon, Jan; van Lingen, Richard A.; Jansman, Frank G. A.; De Jong-van den Berg, Lolkje T. W.; Wilffert, Bob

The effects of a single nucleotide polymorphism in <i>SLCO1B1</i> on the pharmacodynamics of pravastatin
pp. 303-306(4)
Authors: Martin, Nicholas G.; Li, Ka Wah; Murray, Heather; Putt, Wendy; Packard, Chris J.; Humphries, Steve E.

Unlicensed use of metformin in children and adolescents in Germany and France
pp. 307-308(2)
Authors: Kostev, Karel; Richter, Hartmut

Time for clinical trials of epigenetic drugs in psychiatric disorders?
pp. 309-310(2)
Authors: Peedicayil, Jacob; Kumar, Aniket

Atlas of Implantable Therapies for Pain Management
pp. 311-311(1)
Author: Padfield, Nicholas

Basic Pharmacokinetics and Pharmacodynamics, an Integrated Textbook and Computer Simulations
pp. 312-313(2)
Author: Duffull, Stephen

ABSTRACTS OF THE DUTCH SOCIETY OF CLINICAL PHARMACOLOGY AND BIOPHARMACY MEETING OF APRIL 2011
pp. 314-321(8)

Translation Section
pp. 322-330(9)